Brain diseases collectively affect more people than any other category of illness on the planet. A 2021 Global Burden of Disease analysis estimated that roughly 3.4 billion people worldwide had a condition affecting the nervous system, amounting to about 43 percent of the global population.1The Lancet Neurology. Global, regional, and national burden of disorders affecting the nervous system, 1990–2021: a systematic analysis for the Global Burden of Disease Study 2021 That figure spans everything from migraine to dementia to stroke. Understanding which brain diseases are most common, what they look like, and where science stands on treating them is relevant to nearly everyone, whether you are managing your own health or watching someone you love struggle with a diagnosis.
The Global Picture
Neurological disorders are the leading cause of disability and the second leading cause of death worldwide.2PubMed Central. The global burden of neurological disorders: translating evidence into policy In 2021, conditions affecting the nervous system caused an estimated 11.1 million deaths and were the single largest contributor to global disability-adjusted life years, surpassing even cardiovascular disease when stroke is counted in the neurological column.3The Lancet Neurology. Global, regional, and national burden of disorders affecting the nervous system, 1990–2021: a systematic analysis for the Global Burden of Disease Study 2021 And the burden is growing. The absolute number of deaths and people living with disability from neurological diseases has risen substantially over the past three decades, driven by population growth and aging.4PubMed Central. The global burden of neurological disorders: translating evidence into policy
An earlier Global Burden of Disease analysis, using 2016 data, broke down which disorders contributed most to the overall toll. Stroke alone accounted for about 42 percent of all neurological disability, making it the single largest contributor by a wide margin. Migraine came next at roughly 16 percent, followed by Alzheimer’s disease and other dementias at about 10 percent, and meningitis at around 8 percent.5PubMed Central. Global, regional, and national burden of neurological disorders, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016 That ranking surprises many people: migraine, often dismissed as “just a headache,” exacts more total disability than Alzheimer’s, largely because it strikes younger people and persists for decades.
Stroke
Stroke dominates neurological disability statistics because it strikes suddenly, kills brain tissue within minutes, and often leaves survivors with lasting impairments in movement, speech, or cognition. There are two broad types: ischemic stroke, caused by a blood clot blocking an artery to the brain, and hemorrhagic stroke, caused by a ruptured blood vessel bleeding into or around the brain. Ischemic strokes are far more common, accounting for the large majority of cases.
Despite the different underlying mechanisms, rehabilitation outcomes for the two types are more similar than you might expect. A study comparing ischemic and hemorrhagic stroke patients found no significant differences between them at discharge in cognitive and physical abilities, psychosocial adjustment, participation, or overall functioning, and the degree of improvement from admission to discharge was also statistically similar.6PubMed Central. Rehabilitation Outcomes: Ischemic versus Hemorrhagic Strokes That doesn’t mean every individual recovers equally, but the type of stroke alone is a poor predictor of how much ground someone will regain.
Recovery after stroke depends heavily on neuroplasticity: the brain’s capacity to rewire itself. After a stroke, a window opens in which the brain ramps up cell growth, new connections between neurons, and reorganization of existing circuits. This plasticity underlies both the spontaneous improvements that many patients experience in the first weeks and the gains driven by rehabilitation therapy.7PubMed Central. Epigenetic mechanisms of neuroplasticity and the implications for stroke recovery The key therapeutic targets for boosting recovery include promoting new synaptic connections, encouraging cortical reorganization, and stimulating the growth of new nerve fibers.8Journal of Physiology and Biology Sciences. Neuroplasticity in Recovery after Stroke: Mechanisms and Therapeutic Targets This is why early, intensive rehabilitation matters so much: it exploits the brain’s own repair window.
Alzheimer’s Disease and Dementia
Alzheimer’s disease is the most common cause of dementia and the neurodegenerative condition most people fear. It typically begins with subtle memory lapses and progresses to severe cognitive decline, personality changes, and loss of independence. Two hallmark protein abnormalities have long defined the disease: sticky plaques made of amyloid-beta and tangled fibers of a protein called tau inside neurons.
For the past quarter-century, the dominant idea in the field has been that amyloid buildup is the triggering event, setting off a chain reaction leading to tau tangles, neuron death, and eventual symptoms. This “amyloid cascade hypothesis” guided billions of dollars in drug development. Yet therapeutic approaches aimed at lowering amyloid levels have largely failed to stop the disease, and trials targeting tau have also not produced clear benefits.9PubMed Central. Role of Amyloid-β and Tau Proteins in Alzheimer’s Disease: Confuting the Amyloid Cascade Recent anti-amyloid antibodies (such as lecanemab and donanemab) have shown modest slowing of cognitive decline in clinical trials, enough to earn regulatory approval, but the effect sizes are small and the debate about whether amyloid removal translates into meaningful clinical benefit remains heated.
One of the more promising developments is in diagnosis rather than treatment. Blood-based biomarkers, particularly measurements of phosphorylated tau in plasma, can now distinguish Alzheimer’s from other causes of cognitive decline with high accuracy and predict who with early memory complaints will go on to develop full dementia.10PubMed Central. Blood biomarkers for Alzheimer’s disease in clinical practice and trials A simple blood draw that flags Alzheimer’s before symptoms become severe could eventually change the entire clinical workflow, replacing the expensive PET scans and spinal taps currently needed for definitive diagnosis.
Parkinson’s Disease
Parkinson’s disease is best known for its motor symptoms: tremor, stiffness, slowness of movement, and balance problems. These arise from the death of dopamine-producing neurons in a specific brain region called the substantia nigra. A protein called alpha-synuclein clumps into structures known as Lewy bodies inside affected neurons, and this pathology is central to what makes Parkinson’s, Parkinson’s.11PubMed Central. α-Synuclein and dopamine at the crossroads of Parkinson’s disease
But the motor symptoms are only part of the picture. Many patients experience constipation, loss of smell, sleep disturbances, depression, and anxiety years or even decades before the tremor begins. This has led to one of the most intriguing ideas in neuroscience right now: that Parkinson’s, at least in some people, may actually start in the gut rather than the brain. There is growing evidence that early changes in the gut microbiome and accumulation of abnormal alpha-synuclein in the digestive tract could trigger the disease, with the misfolded protein spreading upward to the brain through the nerve connections between the gut and the central nervous system.12PubMed Central. The gut-brain axis in early Parkinson’s disease: from prodrome to prevention
This “body-first” model applies to a subgroup of patients who first present with symptoms like gut dysfunction and sleep problems that precede the classic motor features. Research suggests that in these individuals, pathological alpha-synuclein may spread from the gastrointestinal tract through neural connections along the gut-brain axis, eventually reaching the brain and producing the recognizable disease.13PubMed Central. The Gut-Brain Axis in Parkinson disease: Emerging Concepts and Therapeutic Implications Not everyone with Parkinson’s follows this pattern, but the gut-brain connection has opened up new possibilities for early detection and even prevention.
Migraine
Migraine is wildly underappreciated as a brain disease. It ranks as the second-largest contributor to neurological disability worldwide, yet it is routinely trivialized by employers, insurers, and sometimes even doctors. A migraine attack is not simply a bad headache. It involves inherited changes in brain excitability, activation of pain pathways between the brain and the blood vessels surrounding it, and, in many cases, lasting structural and functional changes in the brain over time.14PubMed Central. Migraine pathophysiology: anatomy of the trigeminovascular pathway and associated neurological symptoms, cortical spreading depression, sensitization, and modulation of pain
In people who experience migraine with aura (the visual disturbances, numbness, or speech changes that sometimes precede the headache), a phenomenon called cortical spreading depression appears to be a key trigger. This is a slow wave of intense neuronal activity followed by suppression that rolls across the surface of the brain, activating pain-signaling pathways as it goes.15PubMed Central. Cortical spreading depression as a site of origin for migraine: Role of CGRP A signaling molecule called CGRP (calcitonin gene-related peptide) is released during this wave and plays a critical role in sustaining both the spreading depression itself and the pain that follows. CGRP receptor blockers have been shown to reduce cortical spreading depression in a dose-dependent manner, and this understanding led directly to the development of a new class of migraine drugs.16PubMed Central. Critical role of calcitonin gene-related peptide receptors in cortical spreading depression The anti-CGRP medications (like erenumab, fremanezumab, and galcanezumab) are now widely used as preventive therapies, and for many people they represent the first treatment that actually addresses the biology of migraine rather than just dulling the pain.
Epilepsy
Epilepsy is defined by recurrent, unprovoked seizures. It affects people of all ages and has dozens of distinct subtypes, ranging from brief absence seizures in children (which look like momentary staring spells) to dramatic convulsive episodes. The underlying issue involves an imbalance in the brain’s electrical signaling: too much excitatory activity, too little inhibitory control, or both, tipping the brain into a state where normal activity suddenly becomes synchronized and out of control.17PubMed Central. Pediatric Epilepsy Mechanisms: Expanding the Paradigm of Excitation/Inhibition Imbalance
Interestingly, recent research has added nuance to this picture. When scientists tracked brain dynamics in the minutes leading up to a seizure, they found a global shift in the brain’s excitation-to-inhibition balance, but the shift was toward greater inhibition rather than less. This change was detectable across both the epileptic and non-epileptic regions of the brain, suggesting the entire brain is involved in the run-up to a seizure, not just the focal area where it originates.18PubMed Central. Dynamic excitation/inhibition balance preceding seizure onset and its link to functional and structural brain architecture This is counterintuitive and suggests the brain may be trying to suppress a seizure right before it happens, with the seizure representing a failure of that suppression rather than a simple surge in excitation.
Most people with epilepsy can achieve good seizure control with medication, and about two-thirds respond well to the first or second drug tried. For those who don’t, options include surgery to remove the brain tissue generating seizures, nerve stimulation devices, and dietary approaches like the ketogenic diet. The challenge is that epilepsy is not one disease but many, and treatment often has to be tailored through trial and error.
Multiple Sclerosis
Multiple sclerosis is the most common demyelinating disease of the central nervous system. The immune system mistakenly attacks myelin, the protective insulation around nerve fibers, causing inflammation and damage that disrupts electrical signals traveling through the brain and spinal cord.19PubMed Central. Myelin recovery in multiple sclerosis: the challenge of remyelination Symptoms depend on where the damage occurs and can include vision problems, numbness, weakness, fatigue, balance trouble, and cognitive difficulties.
MS typically appears between the ages of 20 and 40 and is more common in women. It follows several patterns: relapsing-remitting MS, where symptoms flare and then partially or fully resolve, is the most common form. Over time, many patients transition to a progressive phase where disability accumulates more steadily. Modern disease-modifying therapies have dramatically improved outcomes for the relapsing form, reducing the frequency of attacks and slowing the accumulation of brain lesions. The progressive forms remain harder to treat, and much current research focuses on finding ways to encourage the brain to repair damaged myelin, a process called remyelination that happens naturally but often incompletely.20PubMed Central. Myelin recovery in multiple sclerosis: the challenge of remyelination
Brain Tumors and the Blood-Brain Barrier Problem
Brain tumors are less common than stroke or dementia but often carry a grim prognosis, particularly glioblastoma, the most aggressive primary brain cancer. One of the central frustrations of glioblastoma treatment is the blood-brain barrier, a tightly sealed lining of blood vessels that protects the brain from toxins but also blocks most cancer drugs. For years, there was an assumption that glioblastomas uniformly break down this barrier, since contrast dye leaks into the tumor on brain scans. But a critical review of clinical data found that all glioblastomas also contain a substantial fraction of tumor cells behind an intact blood-brain barrier, and drugs that cannot cross it do not reach those cells at therapeutically effective levels.21PubMed Central. Is the blood–brain barrier really disrupted in all glioblastomas? A critical assessment of existing clinical data This means even when a drug appears promising in the parts of the tumor where the barrier is broken, it likely leaves behind a reservoir of protected cancer cells that will eventually cause relapse.
ALS and the Overlap With Frontotemporal Dementia
Amyotrophic lateral sclerosis (ALS, also known as Lou Gehrig’s disease) destroys the motor neurons that control voluntary movement, leading to progressive paralysis and, eventually, death, usually within a few years of diagnosis. It has long been considered a motor disease, but we now know that ALS shares deep biological roots with frontotemporal dementia, a form of dementia that affects personality, behavior, and language rather than memory.
The link between the two became clear with the discovery that a protein called TDP-43 forms abnormal clumps in the neurons of patients with both sporadic ALS and the most common subtype of frontotemporal dementia. Mutations in the gene encoding TDP-43 have been found in both familial and sporadic ALS cases.22PubMed Central. The role of transactive response DNA-binding protein-43 in amyotrophic lateral sclerosis and frontotemporal dementia Some ALS patients develop clear symptoms of frontotemporal dementia, and some frontotemporal dementia patients develop motor neuron problems. The two diseases are now understood as a spectrum rather than wholly separate conditions.
Traumatic Brain Injury and Chronic Traumatic Encephalopathy
Traumatic brain injury ranges from mild concussions that resolve in days to severe injuries with permanent consequences. An issue that has received enormous public attention is chronic traumatic encephalopathy (CTE), a neurodegenerative disease caused by repetitive head impacts over time. CTE is associated with violent behavior, loss of impulse control, depression, suicidality, memory loss, and progressive cognitive decline.23PubMed Central. Repetitive Head Impacts and Chronic Traumatic Encephalopathy A major limitation in the field is that CTE can currently be diagnosed only by examining brain tissue after death; there is no definitive test for it in a living person. Research into blood and imaging biomarkers that might detect CTE during life is ongoing but has not yet produced a validated clinical tool.
Shared Threads Across Brain Diseases
One of the more striking findings of the past two decades is that many apparently different brain diseases share overlapping biology. Several mechanisms keep turning up across Alzheimer’s, Parkinson’s, ALS, multiple sclerosis, and other conditions, suggesting that the brain has a limited repertoire of ways to go wrong.
Neuroinflammation is the most prominent shared feature. Microglia, the brain’s resident immune cells, play a protective role when activated briefly, cleaning up debris and fighting infection. But when microglia become chronically activated, they release substances that damage surrounding healthy tissue. The dying neurons, in turn, stimulate more microglial activation, creating a self-reinforcing cycle of inflammation and cell death. This destructive loop has been documented in Alzheimer’s, Parkinson’s, Huntington’s disease, and ALS.24PubMed. Microglia-mediated neuroinflammation in neurodegenerative diseases Targeting microglia to break this cycle is now considered a potential strategy for developing future therapies across multiple neurodegenerative diseases.25PubMed Central. Microglia in Neuroinflammation and Neurodegeneration: From Understanding to Therapy
Blood-brain barrier breakdown is another thread running through multiple conditions. Neuroimaging and biomarker studies have demonstrated that the barrier deteriorates in Alzheimer’s, Parkinson’s, Huntington’s, ALS, multiple sclerosis, CTE, and HIV-associated dementia.26PubMed Central. Blood-brain barrier breakdown in Alzheimer disease and other neurodegenerative disorders When this barrier leaks, blood proteins and immune cells that normally stay out of the brain get in and drive further damage. Whether barrier breakdown is a cause, a consequence, or both likely depends on the disease, but it opens a shared therapeutic avenue: drugs or strategies that shore up barrier integrity could theoretically slow several diseases at once.
Emotional and Behavioral Symptoms That Cut Across Diagnoses
People tend to associate each brain disease with a signature physical symptom: tremor for Parkinson’s, memory loss for Alzheimer’s, paralysis for ALS. Less often discussed is that many neurodegenerative diseases produce strikingly similar psychiatric and behavioral symptoms, including anxiety, depression, apathy, disinhibition, and sometimes euphoria. These emotional changes stem from degeneration of overlapping brain circuits, and the overlap with symptoms seen in primary psychiatric disorders is substantial. For instance, the impulsive, disinhibited behavior that appears in frontotemporal dementia involves the same orbitofrontal brain regions implicated in bipolar disorder.27PubMed Central. Emotional and behavioral symptoms in neurodegenerative disease: a model for studying the neural bases of psychopathology
This convergence matters practically. Families often notice personality or mood changes before the classic neurological symptoms appear, and these changes are frequently misattributed to depression, stress, or “just getting older.” Recognizing that apathy or sudden irritability can be an early sign of neurodegeneration rather than a standalone psychiatric condition may lead to earlier diagnosis and more appropriate care.
Lifestyle Factors and Cognitive Reserve
Not all risk for brain disease is written in your genes or determined by chance. A systematic review of the evidence found that lifestyle activity factors can measurably buffer the relationship between brain deterioration and cognitive decline, supporting the idea that staying mentally and physically active may delay the onset of dementia even in people whose brains already show signs of disease.28PubMed Central. Modifiable lifestyle factors and cognitive reserve: a systematic review of current evidence
A cross-sectional study examining how lifestyle maps onto cognitive performance found that four factors in particular were associated with better cognitive function in later life: mentally and socially engaging activities, physical activity, light-to-moderate alcohol consumption, and a healthy diet. About a fifth of the total benefit from these lifestyle factors was mediated through building up what researchers call cognitive reserve, essentially the brain’s ability to tolerate damage before symptoms appear.29PubMed Central. Potentially modifiable lifestyle factors, cognitive reserve, and cognitive function in later life: A cross-sectional study The remaining four-fifths operated through other pathways, suggesting that staying active benefits the brain in ways that go beyond simply building a bigger buffer.
Sleep is another modifiable factor gaining attention. Studies in mice have shown that the brain’s waste-clearance system, called the glymphatic system, is vastly more active during sleep than during wakefulness: protein clearance from the brain roughly doubles during sleep, and glymphatic flow increases by about 80 to 90 percent compared to the waking state, particularly during deep slow-wave sleep.30PubMed Central. The Sleeping Brain: Harnessing the Power of the Glymphatic System through Lifestyle Choices Since several brain diseases involve the buildup of toxic proteins, chronic sleep deprivation may impair the brain’s ability to clear those proteins, adding to the long-term risk.
Emerging Therapeutic Approaches
One of the more exciting frontiers in brain disease treatment is antisense oligonucleotide (ASO) therapy, a type of drug designed to silence or modify the instructions from specific genes. ASOs are in development for ALS, Huntington’s disease, and Alzheimer’s, among others. The approach already has a proof of concept: an ASO drug called nusinersen was approved for spinal muscular atrophy, a devastating motor neuron disease of infancy, and it does not merely slow progression but actually improves symptoms in patients who are already symptomatic.31PubMed Central. Antisense Oligonucleotide Therapies for Neurodegenerative Diseases Translating that success to the far more complex biology of Alzheimer’s or Huntington’s is a much harder problem, but the principle that you can deliver a gene-targeted drug directly into the nervous system and produce real clinical improvement has been established.
Gene therapy, stem cell approaches, and immune-modulating strategies are also under investigation for various brain diseases. The common challenge across all of them is getting therapies into the brain in sufficient quantities. As illustrated by the glioblastoma example, the blood-brain barrier remains a formidable obstacle, and many otherwise promising drugs fail simply because they cannot reach the cells that need them. Novel delivery methods, including engineered viral vectors, nanoparticles, and focused ultrasound to temporarily open the barrier, are active areas of research that could eventually benefit treatment across multiple brain diseases.